Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven D Nathan

Showing results (101-110 of 297) with videos related to

Pageof 30
Sort By:
Chest|January 29, 2026
Pulmonary hypertension prevalence and significance in lung transplant recipients with cystic fibrosis and non-cystic fibrosis bronchiectasisAbhimanyu Chandel, Simon Turkington, Christopher S King, et al.
BMC Pulmonary Medicine|November 22, 2023
Healthcare resource utilization in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD): a real-world data analysisTracey Weiss, Aimee M Near, Xiaohui Zhao, et al.
Respiration; International Review of Thoracic Diseases|February 12, 2004
Interferon gamma-1b as therapy for idiopathic pulmonary fibrosis. An intrapatient analysisSteven D Nathan, Scott D Barnett, Brian Moran, et al.
Pulmonary Circulation|October 4, 2024
COPD associated pulmonary hypertension: A post hoc analysis of the PERFECT studySteven D Nathan, Victoria Lacasse, Heidi Bell, et al.
Pulmonary Circulation|December 29, 2022
Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary HypertensionSteven D Nathan, Peter Fernandes, Mitchell Psotka, et al.
Advances in Therapy|July 5, 2022
The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILDMartin Kolb, Stylianos E Orfanos, Chris Lambers, et al.
Respiratory Research|July 3, 2025
The potential clinical implications of slow vital capacity in patients with idiopathic pulmonary fibrosisHo Cheol Kim, Sydney Guthrie, Christopher S King, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|August 24, 2022
The 6-min walk test as a primary end-point in interstitial lung diseaseSergio Harari, Athol U Wells, Wim A Wuyts, et al.
Pulmonary Circulation|July 17, 2025
Hemodynamic Patterns in Interstitial Lung Disease: A Snapshot of Clinical Practice and a Roadmap for Future TrialsHo Cheol Kim, Christopher S King, Christopher A Thomas, et al.
Respiratory Medicine|May 5, 2018
Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study designJürgen Behr, Steven D Nathan, Sergio Harari, et al.
Pageof 30

Showing results (101-110 of 297) with videos related to

Sort By:
Pageof 30
Chest|January 29, 2026
Pulmonary hypertension prevalence and significance in lung transplant recipients with cystic fibrosis and non-cystic fibrosis bronchiectasisAbhimanyu Chandel, Simon Turkington, Christopher S King, et al.
BMC Pulmonary Medicine|November 22, 2023
Healthcare resource utilization in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD): a real-world data analysisTracey Weiss, Aimee M Near, Xiaohui Zhao, et al.
Respiration; International Review of Thoracic Diseases|February 12, 2004
Interferon gamma-1b as therapy for idiopathic pulmonary fibrosis. An intrapatient analysisSteven D Nathan, Scott D Barnett, Brian Moran, et al.
Pulmonary Circulation|October 4, 2024
COPD associated pulmonary hypertension: A post hoc analysis of the PERFECT studySteven D Nathan, Victoria Lacasse, Heidi Bell, et al.
Pulmonary Circulation|December 29, 2022
Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary HypertensionSteven D Nathan, Peter Fernandes, Mitchell Psotka, et al.
Advances in Therapy|July 5, 2022
The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILDMartin Kolb, Stylianos E Orfanos, Chris Lambers, et al.
Respiratory Research|July 3, 2025
The potential clinical implications of slow vital capacity in patients with idiopathic pulmonary fibrosisHo Cheol Kim, Sydney Guthrie, Christopher S King, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|August 24, 2022
The 6-min walk test as a primary end-point in interstitial lung diseaseSergio Harari, Athol U Wells, Wim A Wuyts, et al.
Pulmonary Circulation|July 17, 2025
Hemodynamic Patterns in Interstitial Lung Disease: A Snapshot of Clinical Practice and a Roadmap for Future TrialsHo Cheol Kim, Christopher S King, Christopher A Thomas, et al.
Respiratory Medicine|May 5, 2018
Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study designJürgen Behr, Steven D Nathan, Sergio Harari, et al.
Pageof 30